Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.35 (
matrix metalloproteinase 9
)
2,207
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nasopharyngeal carcinoma (NPC), which is closely associated with the Epstein-Barr virus (EBV), is a highly metastatic malignant tumor. An important activity in tumor invasion and metastasis is that of the
92-kDa type IV collagenase
or gelatinase,
matrix metalloproteinase 9
(
MMP-9
), which mediates the degradation of the basement membrane and extracellular matrix. The expression of
MMP-9
has been shown to be enhanced by the EBV oncoprotein, latent membrane protein 1 (LMP-1). LMP-1, which is expressed in NPC, has two essential signaling domains within the carboxy terminus, termed C-terminal activation regions 1 (CTAR-1) and CTAR-2. This study reveals that either signaling domain can activate the
MMP-9
promoter and induce
MMP-9
activity; however, LMP-1 deletion mutants lacking either CTAR-1 or CTAR-2 had a decreased ability to induce
MMP-9
expression. The deletion of both activation regions completely abolished the induction of
MMP-9
activity, while the cotransfection of both the CTAR-1 and CTAR-2 deletion mutants restored
MMP-9
activity to levels produced by wild-type LMP-1. The NF-kappaB and activator protein 1 (AP-1) binding sites in the
MMP-9
promoter were essential for the activation of
MMP-9
gene expression by both CTAR-1 and CTAR-2. The induction of
MMP-9
expression by LMP-1 and both CTAR-1 and CTAR-2 mutants was blocked by the overexpression of IkappaB. The tumor necrosis factor receptor-associated factor (TRAF) pathway also contributed to the activation of the
MMP-9
promoter as shown by the use of TRAF-2 and
TRAF-3
dominant-negative constructs. These data indicate that the activation of both the NF-kappaB and AP-1 pathways by LMP-1, CTAR-1, and CTAR-2 is necessary for the activation of
MMP-9
expression. In NPC, LMP-1 may contribute to invasiveness and metastasis through the induction of
MMP-9
transcription and enzymatic activity.
...
PMID:Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2. 1036 3